Quinestrol (Estrovis)

Subscribe to Selected New Research on Quinestrol

14 relevant articles (0 outcomes, 2 trials/studies) found for this Drug

Description: The 3-cyclopentyl ether of ETHINYL ESTRADIOL. After gastrointestinal absorption, it is stored in ADIPOSE TISSUE, slowly released, and metabolized principally to the parent compound. It has been used in ESTROGEN REPLACEMENT THERAPY. (From AMA Drug Evaluations Annual, 1992, p1011)

Also Known As:

Estrovis; Parke Davis Brand of Quinestrol; Ethinyl Estradiol 3 Cyclopentyl Ether; Ethinyl Estradiol 3-Cyclopentyl Ether; 19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-(cyclopentyloxy)-, (17alpha)-

Drug Context: Research Results

Related Diseases

1.	Syndrome 01/01/1979 - "This study used quinestrol in 1 mg monthly oral doses in a group of women (N=70) suffering from the menopausal syndrome (43 from spontaneous and 27 from surgical menopause)" 01/01/1979 - "The treatment of postmenopausal syndrome by monthly oral doses of quinestrol." 04/01/1967 - "Quinestrol and the menopausal syndrome." Order ALL the reference details at left...
2.	Hemorrhage 07/01/1980 - "The bleeding pattern showed no statistical significance between the quinestrol-treated group and placebo group in terms of the overall effects on the following definitions: acceptable bleeding, amenorrhea, irregular bleeding and prolonged bleeding" 07/01/1980 - "Hence, the use of quinestrol in this trial did not significantly change the bleeding pattern of depot-medroxyprogesterone acetate users." 09/01/1972 - "In order to induce periodic hemorrhage, 6 mg of the synthetic progestogen ethynodiol diacetate was added to the Quinestrol" 07/01/1980 - "In a double-blind clinical trial the effect on the bleeding pattern disrupted by progesterone-only injectable contraception of quinestrol, an estrogen which is stored in body fat and is slowly released over days, was studied in 236 Thai women giving informed consent and having irregular or nonexistent bleeding patterns since the start of Depo-Provera contraception" Order ALL the reference details at left...
3.	Infertility (Sterility) 04/01/1970 - "Quinestrol therapy in cervical factor sterility]" 04/01/1967 - "Quinestrol therapy in functional infertility." 07/01/1966 - "Quinestrol therapy in functional infertility." 02/01/1971 - "Combined therapy with quinestrol and clomiphene in functional sterility." Order ALL the reference details at left...
4.	Hyperplasia 01/01/1976 - "Cystic hyperplasia was found to occur spontaneously, particularly in nonlactators, and with greater severity in patients who had received a long-acting estrogenic agent (quinestrol) for lactation suppression." 02/01/1970 - "Endometrial biopsies indicated by their lack of hyperplasias that the quinestrol did not accumulate." Order ALL the reference details at left...
5.	Amenorrhea 03/01/1975 - "Post-partum amenorrhea showed a progressive prolongation from an average of 47.9 days in the controls to 64.6 and 72.6 days respectively in the 2 and 4 mg quinestrol groups" 07/01/1980 - "The bleeding pattern showed no statistical significance between the quinestrol-treated group and placebo group in terms of the overall effects on the following definitions: acceptable bleeding, amenorrhea, irregular bleeding and prolonged bleeding" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Medroxyprogesterone 17-Acetate (Depo-Provera)
2.	Progesterone
3.	Ethynodiol Diacetate
4.	Estrogens (Estrogen)
5.	Clomiphene (Clomifene)

Related Therapies and Procedures

1.	Contraception (Birth Control)

Best Treatments:
Research Summary Report
on Syndrome

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a gla